Novartis stock heads into the open after a 3.3 percent slide
Published on 09/08/2026 at 07:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock closed the last session on the SIX Swiss Exchange at around CHF 125.02 on September 7, 2026, down roughly 3.3 percent from the prior close after a sharp intraday decline of about 3.9 percent earlier in the day.Investing.com That close left the share trading near the session low around CHF 124.60 and clearly below the recent 52-week high near CHF 132.68 reached only a few days before.Investing.com European equities overall were muted at the end of the day, with the Stoxx Europe 600 index near 649.90 points and almost unchanged in percent terms, meaning Novartis underperformed the regional benchmark on September 7, 2026.MarketScreener overview of the Stoxx Europe 600
September 7, 2026 in numbers
Novartis AG (ISIN CH0012005267) came under pressure in the last completed session after new cardiovascular data disappointed investors.Bloomberg News The company reported that its experimental heart drug pelacarsen failed to meet a key goal in a closely watched late-stage outcomes study, undermining expectations for a potential blockbuster therapy in high-risk patients and raising questions about the therapeutic approach.Bloomberg News Market data showed the stock falling as much as 3.9 percent intraday and settling near CHF 125.02 at the close, with the day’s trading range clustered between roughly CHF 124.60 at the low and CHF 132 at the upper end, leaving the share several francs below its recent 52-week peak around CHF 132.68.Investing.com In contrast, the Stoxx Europe 600 index finished the session near 649.90 points and flat in percent terms, so Novartis clearly lagged the broader European market on September 7, 2026.MarketScreener overview of the Stoxx Europe 600
Today’s drivers for Novartis
Heading into today’s session on September 8, 2026, investors are focused on the fallout from the pelacarsen trial miss and what it implies for Novartis’s broader cardiovascular pipeline, as well as for upcoming gene therapy data highlighted in recent commentary.Reuters report on cholesterol study Analysts are beginning to react to the new information, with at least one major house maintaining a positive stance while setting a price target of CHF 142.00 and framing the setback within a diversified pipeline view.TipRanks summary of Citi research More broadly, European market sentiment today is shaped by firm energy prices and geopolitical tensions that were already weighing on regional indices at the start of the week, factors that can influence defensively oriented healthcare shares like Novartis through shifts in risk appetite and sector rotation.Sina Finance European market wrap
